Navigation Links
Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
Date:9/12/2011

utions received a major boost. While all three of our in-clinic molecules performed admirably, Btk Inhibitor PCI-32765 was in all forms of measurement truly outstanding. We plan to initiate our first Phase III trial for 32765 in this fiscal year ending June 30, 2012. We currently also plan to initiate a second Phase III during calendar year 2012. In terms of human and financial capital we are in good shape. Opportunity attracts great people and so it is the case with us. Our expanding team continues to be very focused on building a viable pharmaceutical company that makes a truly significant difference for the better." said Bob Duggan, CEO and Chairman of the Board. "We at Pharmacyclics take great pride in our accomplishments over the past few years and we maintain a keen sense of obligation and enthusiasm as we create our future."

Recent Developments & HighlightsBruton's Tyrosine Kinase (Btk) Inhibitor for Oncology

  • Results from our Phase IB/II trial of PCI 32765 in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) were presented at an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois in June 2011. As reported at the meeting, treatment with PCI-32765 was generally well-tolerated.  The most common adverse events were Grade 1 (mild) or Grade 2 (moderate) diarrhea, fatigue, and nausea. Durable anti-tumor activity was also observed; 3 of 83 patients who were evaluable at the time of presentation had experienced disease progression.  An abstract with an updated analysis of this trial has been submitted for the 2011 American Society of Hematology (ASH) Annual Meeting to be held in San Diego in December, 2011.

  • In August 2011, we entered into a five-year Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to collaborate on the development of PCI-32765.  Under the Agreement, the NCI's Division of Cancer
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
    2. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
    3. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
    4. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
    5. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
    6. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
    7. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
    8. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
    9. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
    10. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
    11. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/24/2015)... 2015   Bernstein Liebhard LLP is ... the "Company") (NASDAQ: AERI ) issued materially ... of the federal securities laws; or (ii) the ... duties to shareholders. Aerie is a ... and commercialization of first-in-class therapies for the treatment ...
    (Date:4/24/2015)... 24, 2015  A new study shows an "alarming rise" ... used to slow the progression of multiple sclerosis or reduce ... researchers at Oregon Health & Science University (OHSU) and Oregon ... number of MS drugs in the marketplace over the past ... costs for patients who use those drugs. Researchers found the ...
    (Date:4/24/2015)... --  Vestagen Technical Textiles, Inc. today announced that ... received two notable innovation awards. The first is the ... with potential to create a positive impact in the ... New York City , VESTEX received the Silver ... category. The awards honor excellence in new product and ...
    Breaking Medicine Technology:Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Aerie Pharmaceuticals, Inc. 2Researchers find alarming rise in cost of MS drugs over past two decades 2Researchers find alarming rise in cost of MS drugs over past two decades 3Researchers find alarming rise in cost of MS drugs over past two decades 4VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 2VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 3
    ... 2011 Abaxis, Inc. (NasdaqGS: ABAX), a medical products company ... to discuss its financial results for the second quarter of ... be at 4:15 p.m. ET on Tuesday, October 25, 2011. ... of fiscal year 2012 after the market closes on Tuesday, ...
    ... Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), a specialty ... on Monday, October 31, 2011 before the opening of the ... call that day at 10:00 a.m. ET to discuss results ... to be used during the call will be available on ...
    Cached Medicine Technology:Abaxis to Report Second Quarter Fiscal Year 2012 Financial Results Tuesday, October 25, 2011 2Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011 2Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011 3
    (Date:4/25/2015)... April 26, 2015 The National ... , a national endeavor to prepare nurses to provide ... a great success, according to a new report by ... original funding partners. , The project began in ... (CCP), under the direction of Elaine Tagliareni, EdD, RN, ...
    (Date:4/25/2015)... The Hon. Ellen Tauscher, Independent Chair of ... statement following the deadly earthquake in Nepal: , "Today ... the deaths of more than 1,000 people. The ... Bangladesh, India and other parts of South Asia. ... people of Nepal and the families of the victims. ...
    (Date:4/25/2015)... 2015 By definition, a CIO’s responsibility is ... enterprise relying on their judgement and expertise to keep digital ... to an article published in National Mortgage News on ... doing a disservice to their responsibilities by focusing too heavily ... are crossed when it comes to company policy and industry ...
    (Date:4/25/2015)... Parker and Sons projects growth in 2015. ... in Arizona alongside the growing economy. As a result, Parker ... April to help account for the rising need for heating, ... is something we are enthusiastic about. It means growth for ... at Parker and Sons. , Indeed, Parker and Sons has ...
    (Date:4/25/2015)... For thirteen years, the Twin Cities DI ... event in the nation! This year, on May 5th, 2015, ... to take DI Day on the road by supporting the ... ChFC, RHU, DIA, CLTC, Chief Executive Officer at Secura Consultants ... the change by stating, "The first Twin Cities DI Day ...
    Breaking Medicine News(10 mins):Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Parker and Sons Plans to Expand in 2015 2Health News:Secura Consultants Takes DI Day On The Road 2
    ... NEW YORK, June 10 Tongji Healthcare, Inc.,(OTC Bulletin ... in China, reports that its hospital are enjoying an,influx ... province., Due to its status as a private ... Beijing that he has suggested the government would,pick up ...
    ... As nearly 80 percent of adults,experience back pain ... Carolina this month will launch a free, back care ... of the most common medical problems and affects eight,out ... In South Carolina, back,disorders were among the top causes ...
    ... of patients with testicular cancer are cured nowadays, but ... survivors, the medical profession and national governments, a cancer ... on Teenage and Young Adult Cancer Medicine, which is ... and 10). , Dr Craig Nichols, director of program ...
    ... The Endocrine Society will present Ronald S. ... Biomedical Research Institute at Harbor-UCLA Medical Center (LA ... annual convention June 15-18 in San Francisco. , ... members representing the full range of disciplines associated ...
    ... But their tech savvy helps them use online programs ... June 10 (HealthDay News) -- Insomnia among U.S. combat ... seen in patients with chronic insomnia, according to University ... post-deployment adjustment disorders to 14 insomnia patients and 14 ...
    ... Mylan Inc. (NYSE: MYL ),announced today ... agreement with,NATCO Pharma Ltd. (NATCO) for NATCO,s glatiramer ... which is used to treat,multiple sclerosis. The agreement ... and all major markets in Europe, Australia, New,Zealand, ...
    Cached Medicine News:Health News:Tongji Healthcare Services Reports Influx of Patients 2Health News:BlueChoice HealthPlan to Launch Back Care Program 2Health News:Experts highlight gaps in knowledge on caring for survivors of teenage and young adult cancers 2Health News:Experts highlight gaps in knowledge on caring for survivors of teenage and young adult cancers 3Health News:Experts highlight gaps in knowledge on caring for survivors of teenage and young adult cancers 4Health News:LA BioMed investigator wins Distinguished Educator Award 2Health News:Combat Vets Display Severe Sleep Disorders 2Health News:Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R) 2
    The Guidant Fineline EZ leads with protective capsule are bipolar endocardial and designed for permanent implantation with pulse generators for cardiac pacing....
    Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
    ... The Model 6491 unipolar ... designed for temporary atrial and ... and after cardiac surgery. This ... downsized, making it the ideal ...
    ... Guidant Flextend lead is ... lead with an extendable/retractable ... helix design offers various ... permanent implantation in the ...
    Medicine Products: